Ok, we are the NFL of cancer, as I usually say, but this is interesting for all the warriors with no metastasis...
Phase 3 EMBARK trial post-hoc analysis highlights enzalutamide's effectiveness in rapidly achieving and maintaining undetectable PSA levels in patients with high-risk biochemically recurrent prostate cancer.
Patients treated with enzalutamide, alone or combined with leuprolide, had notably better outcomes than those receiving leuprolide alone.
These benefits also correlated with improved metastasis-free survival, emphasizing enzalutamide's clinical potential for aggressive prostate cancer management.
Interestingly: robust PSA control is linked to improved metastasis-free survival independently from the treatment.
Welcoming New Era of Expanded Use of Radiotherapies
